We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
David Fisher

David E Fisher MD, PhD

Chairman, Department of Dermatology, Director, Cutaneous Biology Research Center, Chair, Executive Committee on Research, Director, Melanoma Clinic, Mass General Hospital Cancer Center, Edward Wigglesworth Professor of Dermatology, Harvard Medical School, Boston, MA

David E. Fisher, MD, PhD, is chief of the Massachusetts General Hospital Department of Dermatology. He also serves as director of Mass General’s Cutaneous Biology Research Center, director of the Melanoma Center and as Chair of the MGH Executive Committee on Research. A professor of dermatology and of pediatrics at Harvard Medical School, Dr. Fisher came to Mass General from the Dana-Farber Cancer Institute, where he previously directed the melanoma program. Dr. Fisher’s research has focused on understanding the molecular and genetic events which underlie formation of melanoma as well as skin pigmentation. As a clinician, he has worked to translate these understandings into advances in diagnosis, treatment and prevention of human diseases related to the skin and associated disorders.

Disclosures

Disclosure:  Dr. Fisher has a financial interest in Soltego, Inc., a company developing SIK inhibitors for topical skin darkening treatments that might be used for a broad set of human applications. Dr. Fisher’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies.